<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Energenesis Biomedical Co., Ltd. — News on 6ix</title>
    <link>https://6ix.com/company/energenesis-biomedical-co-ltd</link>
    <description>Latest news and press releases for Energenesis Biomedical Co., Ltd. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 01 Aug 2025 07:52:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/energenesis-biomedical-co-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68367df178dffbe2df1671a0.webp</url>
      <title>Energenesis Biomedical Co., Ltd.</title>
      <link>https://6ix.com/company/energenesis-biomedical-co-ltd</link>
    </image>
    <item>
      <title>Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson&apos;s Disease</title>
      <link>https://6ix.com/company/energenesis-biomedical-co-ltd/news/energenesis-biomedical-announces-positive-phase-075200128</link>
      <guid isPermaLink="true">https://6ix.com/company/energenesis-biomedical-co-ltd/news/energenesis-biomedical-announces-positive-phase-075200128</guid>
      <pubDate>Fri, 01 Aug 2025 07:52:00 GMT</pubDate>
      <description>Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration therapeutics, today announced the successful completion of its Phase I clinical trial for ENERGI-F705PD, an oral investigational drug candidate for Parkinson&apos;s disease (PD). The Phase I study demonstrated favorable safety and tolerability in healthy volunteers, marking a significant milestone in the development of ENERGI-F705PD and reaffirming its potential as a disease-mo</description>
    </item>
  </channel>
</rss>